Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

It’s back to school for biotech, with a packed conference schedule.

A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.

But there are no hard facts, and a Ligand obligation clouds future licensing economics.